Klassen Preston
SEC insider (Form 3/4/5 filer). CIK 0001493056. President & Head of R & D at Regulus Therapeutics Inc. (RGLS). 6 reported Form 4/5 transactions since Sep 2024; latest on Jun 25, 2025. Located in SAN DIEGO, CA.
Companies Klassen Preston has filed insider reports for
- Regulus Therapeutics Inc. (RGLS): Director, Officer, President & Head of R & D
Klassen Preston
CIK: 0001493056
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Regulus Therapeutics Inc.
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Jun 25, 2025RGLS
Regulus Therapeutics Inc.
DispositionDirect115.6K shares- - Jun 3, 2025RGLS
Regulus Therapeutics Inc.
PurchaseDirect12K shares at avg. $7.99$96K - Jan 30, 2025RGLS
Regulus Therapeutics Inc.
AwardDirectStock Option (Right to Buy)
675K shares- - Jan 13, 2025RGLS
Regulus Therapeutics Inc.
SaleDirect31.4K shares at avg. $1.26$40K - Jan 9, 2025RGLS
Regulus Therapeutics Inc.
AwardDirect37.5K shares at avg. $1.36$51K - Jan 9, 2025RGLS
Regulus Therapeutics Inc.
AwardDirect30K shares at avg. $1.30$39K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 25, 2025 | RGLS Regulus Therapeutics Inc. | Disposition | 115,555 | - | - | Direct |
| Jun 3, 2025 | RGLS Regulus Therapeutics Inc. | Purchase | 12,000 | $7.99 | $95,852 | Direct |
| Jan 30, 2025 | RGLS Regulus Therapeutics Inc. | Award Stock Option (Right to Buy) | 675,000 | - | - | Direct |
| Jan 13, 2025 | RGLS Regulus Therapeutics Inc. | Sale | 31,445 | $1.26 | $39,721 | Direct |
| Jan 9, 2025 | RGLS Regulus Therapeutics Inc. | Award | 37,500 | $1.36 | $51,000 | Direct |
| Jan 9, 2025 | RGLS Regulus Therapeutics Inc. | Award | 30,000 | $1.30 | $39,000 | Direct |
1-6 of 6 transactions